AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02150525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO(by mouth)daily
Study NCT02150525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Measures of self-reported outcomes: Self-reported symptoms will be documented with the Urogenital Atrophy Questionnaire (UAQ), Menopausal Rating Scale (MRS), Female Sexual Function Index (FSFI), Center for Epidemiological Studies Short Depression Scale (CES-D 10), and Brief Pain Inventory (BPI).
Study NCT02150525 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire administration
Description: Measures of self-reported outcomes: Self-reported symptoms will be documented with the Urogenital Atrophy Questionnaire (UAQ), Menopausal Rating Scale (MRS), Female Sexual Function Index (FSFI), Center for Epidemiological Studies Short Depression Scale (CES-D 10), and Brief Pain Inventory (BPI).
Study NCT03100201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Armeo®Spring
Description: The robotic-assisted training will be performed using the clinically evaluated Armeo®Spring medical device (Hocoma AG, Zurich, Switzerland). By means of a sensory orthosis, arm movements will be supported and transmitted to a computer system and visually shown on a screen.
Study NCT03100201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group will receive conventional occupational- and physiotherapy over 3 weeks
Study NCT00786123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: Dose: 4 capsules of VSL#3 daily for 6 weeks.
Study NCT00786123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical looking preparation of placebo taken at the same dose regimen as the active comparator
Study NCT02468596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QTRAC assessment
Description: Computerized analysis of the muscular response of musculus abductor pollicis brevis, to series of electrical stimulations of the median nerve
Study NCT02468596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment of peripheral nerve function
Description: Clinometric assessment using RT-MRC, Martin vigirometer, RT-mISS, T25W, 9 hole peg test, and ataxia scale
Study NCT00814567 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
Study NCT00814567 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
Study NCT04085796 — intervention group
Intervention type: OTHER
Intervention: ICCI
Description: Intentional Compassionate Communication Intervention
Study NCT00395889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation including structured exercise training
Description: Rehabilitation of at least 8 weeks, for at least twice/week. This group will also receive the exercise counseling as a part of the rehabilitation program.
Study NCT00395889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Counseling
Description: Six exercise counseling sessions will be carried out during a 6-month period. This group will only receive the counseling and no formal structured exercise training sessions.
Study NCT00936403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: One single dose administered in four dose levels in an escalating order
Study NCT00936403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: A daily dose of Norditropin NordiFlex® for seven days. Dose will remain constant
Study NCT04056065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: In addition to standard of care normal saline to be used as vehicle in the phase-II study to assess efficacy of PMZ-2010 as a resuscitative agent for hypovolemic shock
Study NCT04056065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centhaquine
Description: In addition to standard of care PMZ-2010 to be used as an experimental drug in the phase-II study to assess its efficacy as a resuscitative agent for hypovolemic shock
Study NCT04298242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2100
Description: A non-invasive thermal ablation device fully integrated with an MR imaging system
Study NCT02342028 — intervention group
Intervention type: BIOLOGICAL
Intervention: OSA
Description: This study aims to compare the difference in the number and function of regulatory T cells between OSA patients and controls. The investigators will draw peripheral venous blood samples from both groups and measure the number and function of their regulatory T cells. However, some, NOT ALL, of OSA patients may receive continuous positive airway pressure (CPAP) treatment-the standard therapy for severe-to-moderate OSA. Use of CPAP is based on physician's suggestion and patients' decision, but not for this study. The devices are provided by patients themselves and its type/brand is not limited or prespecified. For those with CPAP therapy, their blood sample will be re-collected 26 weeks later to repeat measurement for subgroup analysis.
Study NCT01177371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given orally
Study NCT01177371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01177371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.
Study NCT01177371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV or orally
Study NCT01177371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT01177371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or orally
Study NCT00304551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a 180μg
Description: 180μg（s.c.）/week for 48 weeks
Study NCT00304551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a 90μg
Description: 90μg(s.c.)/week for 48 weeks
Study NCT00304551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 600, 800, or 1,000 mg X 2(p.o.)/day
Study NCT04948372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin treatment
Description: Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
Study NCT04948372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.
Study NCT01774396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emervel® Touch
Description: Emervel® Touch will be injected only in the intervention group.
Study NCT01774396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emervel® Volume Lidocaine and Emervel® Deep Lidocaine
Description: Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.
Study NCT01774396 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Emervel® Volume Lidocaine and Emervel® Deep Lidocaine
Description: Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.
Study NCT02877992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian puncture
Description: Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.
Study NCT02877992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian puncture
Description: Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.
Study NCT01504490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017 and Bexarotene
Description: CS-7017 will be administered orally, twice daily for 28 days of each 28-day cycle in escalating doses depending on cohort patient is assigned to.~Bexarotene will be administered orally once daily for 28 days of each 28-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to.
Study NCT00268307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous, Unfractionated Bone Marrow Mononuclear Cells
Description: Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
Study NCT02704364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Study NCT02704364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02071394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon gas
Description: Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
Study NCT02071394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body cooling
Description: Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
Study NCT02071394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body cooling
Description: Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
Study NCT03051178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Responsive deep brain stimulation
Description: Responsive deep brain stimulation (R-DBS) therapy will be delivered responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
Study NCT02622126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyethyl starch (6% 130/0.4)
Description: preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).
Study NCT02622126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine
Description: Sub arachnoid 10-12 mg hyperbaric bupivacaine
Study NCT02622126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Sub arachnoid 200 meg morphine
Study NCT02622126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic 0.9 sodium chloride (NaCl) solution
Description: 10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation
Study NCT01610687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-1000-02
Description: Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
Study NCT00839709 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling
Description: peripheral blood draw
Study NCT02622126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: If severe hypotension (fall of > 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.
Study NCT01022502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: refined indigo naturalis ointment
Description: The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
Study NCT01022502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crude indigo naturalis ointment
Description: The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
Study NCT02863627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newborn Care Pathway
Description: consultation with the pediatric emergency, two telephone interviews to complete Questionnaires with the parents after the emergency department visit
Study NCT04557319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-038, 25 МЕ/kg
Description: 25 МЕ/kg once per study
Study NCT04557319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-038, 50 МЕ/kg
Description: 50 МЕ/kg once per study
Study NCT04557319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-038, 100 МЕ/kg
Description: 100 МЕ/kg once per study
Study NCT02622126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Bradycardia (fall of >30% of heart rate from baseline or \<50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.
Study NCT01454102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT00579683 — intervention group
Intervention type: OTHER
Intervention: Tumor core biopsy for RNA isolation
Description: RNA isolation will be carried out using approximately 25 mg of gross tissue from these tumor specimens.
Study NCT01454102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01454102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01454102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT01454102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01454102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01148706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiSight Needle Guidance System
Description: The ActiSight™ Needle Guidance System employs a miniature video camera mounted on the needle and a reference pad attached to the skin to register the needle into the CT image space, and thus, track the needle advance towards the target. CT scans are used as needed to verify the location of the needle.
Study NCT03533413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined CT-fluroscopy
Description: Radiofrequency ablation of thoracic dorsal root ganglia guided by combined CT-Fluroscopy
Study NCT03533413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard fluroscopy
Description: Radiofrequency ablation of thoracic dorsal root ganglia guided by standard fluroscopy only
Study NCT02478905 — intervention group
Intervention type: OTHER
Intervention: Influenza
Study NCT01454102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01454102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT01454102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT00518427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Lantus (insulin glargine \[rDNA origin\] injection), individual dosing , subcutaneous injection, 100 IU/ml.~Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment.
Study NCT02013453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 40mg of Omeprazole will be administered daily by mouth.
Study NCT02013453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40mg of Omeprazole will be administered daily by mouth.
Study NCT02013453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered over 30 minutes by continuous infusion.
Study NCT02013453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered over 30 minutes by continuous infusion.
Study NCT02013453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU
Description: Administered by infusion.
Study NCT02013453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: Administered by infusion.
Study NCT02013453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered by infusion.
Study NCT02013453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by infusion.
Study NCT02013453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered by infusion.
Study NCT02013453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered by infusion.
Study NCT03281967 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Minimally Invasive Ponto Surgery
Description: Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implant in patients indicated and counselled for Bone Anchored Hearing System.
Study NCT04862624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Catalina Story-Based Web-App
Description: Latinas in the experimental group will view a story-based web-app featuring a character named Catalina and psycho-therapeutic modules to motivate them to take action and get help for their symptoms of depression and/or anxiety.
Study NCT04862624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Web-App
Description: Latinas in the attention control group will view non-story based media that is informational.
Study NCT01294150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroLift System
Description: The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
Study NCT01294150 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cystoscopy
Description: The Control Group will undergo cystoscopy.
Study NCT01294150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crossover
Description: Subjects crossed over and received the UroLift System from the Control Group.
Study NCT02770443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: withdrawal
Description: withdrawal of beta blocker and ACE inhibitors
Study NCT02770443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard of CARE
Description: STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY
Study NCT00252304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc (zinc sulphate)
Description: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
Study NCT00252304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05110339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine plus dexmedetomidine
Description: Erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg.
Study NCT05110339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Erector spinae block with ropivacaine at a dose of 0.5%.
Study NCT04711798 — intervention group
Intervention type: OTHER
Intervention: passive leg raising maneuver (PLR)
Description: Passive leg raising maneuver (PLR) for preload status evaluation using the PICCO system will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
Study NCT04711798 — intervention group
Intervention type: OTHER
Intervention: lung recruitment maneuver (LRM)
Description: lung recruitment maneuver (LRM) will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
Study NCT04711798 — intervention group
Intervention type: OTHER
Intervention: echographic evaluation of the right cardiac function
Description: echographic evaluation of the right cardiac function will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).